New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
March 24, 2014
07:12 EDTMYGN, TSROMyriad Genetics announces HRD collaboration with TESARO
Myriad Genetics (MYGN) announced that Tesaro (TSRO) will use Myriad's novel HRD, or homologous recombination deficiency, test to identify tumor types that may respond to its investigational poly-ADP ribose polymerase, or PARP, inhibitor, niraparib, currently in Phase 3 clinical development. Specific terms of the deal were not disclosed.
News For MYGN;TSRO From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
February 24, 2015
16:28 EDTMYGNMyriad Genetics board approves $200M increase in share buyback program
Subscribe for More Information
February 23, 2015
06:25 EDTTSROMedivation removed from Focus List at Citigroup
Subscribe for More Information
06:23 EDTTSROCiti ups TESARO price target to $79, adds to focus list
Subscribe for More Information
February 20, 2015
05:53 EDTTSROTESARO price target raised to $50 from $44 at Mizuho
Mizuho raised its price target for TESARO shares to $50 citing increased confidence and market opportunity for niraparib following the company's Q4 results. The firm expects approval for rolapitant in Q3 and reiterates a Buy rating on the stock.
February 19, 2015
16:13 EDTTSROTESARO reports Q4 EPS ($1.33), consensus ($1.03)
Subscribe for More Information
February 17, 2015
10:53 EDTMYGNScopia Capital reports 5.87% passive stake in Myriad Genetics

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use